Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Tiltan Pharma Announces Enrollment of First U.S. Patient in a Phase 2 Clinical Trial of TL-118

Published: Thursday, March 21, 2013
Last Updated: Thursday, March 21, 2013
Bookmark and Share
White Plains Hospital is the first U.S. site to offer this innovative treatment to cancer patients.

Tiltan Pharma Ltd. has announced that it has enrolled the first U.S. patient, at White Plains Hospital in Westchester County N.Y., in a Phase 2 clinical trial of its anti-angiogenic product, TL-118, for the treatment of metastatic pancreatic cancer.

The Phase 2 study is already ongoing in four major oncology centers in Israel: The Tel Aviv Sourasky Medical Center, Hadassah Medical Center, Assaf HaRofeh Medical Center and the Rambam Medical Center.

The clinical trial will enroll 80 patients with newly diagnosed metastatic pancreatic cancer that have not yet been treated with chemotherapy.

The trial includes two treatment groups with 40 subjects each. The control group is allocated to standard chemotherapy for pancreatic cancer, and the treatment group receives TL-118 in addition to standard-of-care chemotherapy.

Dr. Dan Costin, Director Westchester Institute for Treatment of Cancer and Blood Disorders, Co-Medical Director of White Plains Hospital Cancer Program and Principal Investigator for the TL-118 Study at White Plains Hospital, said: "We are happy to introduce this cutting edge therapy to our pancreatic cancer patients. Unfortunately, metastatic pancreatic cancer is a disease with very poor prognosis and we are urgently seeking new solutions that might enhance survival.

Dr. Costin added, “TL-118, which belongs to the family of angiogenesis inhibiting drugs demonstrated outstanding efficacy in pre-clinical studies, a promise we hope will be translated into significant clinical benefit to people suffering from pancreatic cancer."

Dr. Dan Goldstaub, Tiltan's Chief Operating Officer, said, "We are very pleased with the addition of the U.S. site to our study. The trial is advancing as planned, and we are satisfied with the recruitment rate. In Israel 15 patients were already enrolled, and we are certain that the new U.S. site will expedite the clinical trial. We are closely monitoring the efficacy, safety and tolerability of the product and so far we are happy with the outcome."

TL-118 was initially tested in a mouse model of pancreatic cancer. In these pre-clinical studies, TL-118 monotherapy has been shown to inhibit tumor growth significantly, compared to the standard-of-care chemotherapy.

Moreover, TL-118 therapy in combination with the standard-of-care chemotherapy has eliminated the tumors in all treated animals.

TL-118 inhibits new blood vessel formation in tumors and thus inhibits their blood supply and growth.

TL-118 is formulated as an oral solution administered once daily at home. It is comprised of a combination of agents that target different, non-overlapping aspects of the angiogenic process, all of which are approved by the regulatory authorities.

The therapy cycle is a carefully timed and balanced, patient-friendly treatment regimen that maximizes the synergistic effect of these agents and combines them into a single, safe and effective cancer treatment. More than 100 cancer patients have been treated with TL-118 so far, for up to four years.

TL-118 was previously tested for safety in a Phase 1 clinical trial that was conducted in the Sheba Medical Center at Tel-HaShomer, Israel.

Thirty cancer patients were enrolled in the trial and the therapy was found to be safe and tolerable for the treatment of cancer patients and caused mostly minor clinically significant adverse reactions.

Tiltan Pharma is one of the portfolio companies of Integra Holdings, a biopharmaceutical holding company founded by Yissum, the technology transfer company of the Hebrew University of Jerusalem.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Tiltan Pharma Commences Phase 2 Clinical Study of Anti-Angiogenic Treatment for Pancreatic Cancer
Clinical trial will enroll 80 patients with newly diagnosed metastatic pancreatic cancer.
Thursday, May 24, 2012
Scientific News
Common Cell Transformed into Master Heart Cell
By genetically reprogramming the most common type of cell in mammalian connective tissue, researchers at the University of Wisconsin—Madison have generated master heart cells — primitive progenitors that form the developing heart.
Genetic Mutation that Prevents Diabetes Complications
The most significant complications of diabetes include diabetic retinal disease, or retinopathy, and diabetic kidney disease, or nephropathy. Both involve damaged capillaries.
Could the Food we Eat Affect Our Genes?
Almost all of our genes may be influenced by the food we eat, according to new research.
Neanderthal DNA Influences Human Disease Risk
Large-scale, evolutionary analysis compares genetic data alongside electronic health records.
Improving Regenerative Medicine
Lab-created stem cells may lack key characteristics, UCLA research finds.
Tick Genome Reveals Secrets of a Successful Bloodsucker
NIH has announced that decipher the genome of the blacklegged tick which could lead to new tick control methods.
"Dark Side" of the Transcriptome
New approach to quantifying gene "read-outs" reveals important variations in protein synthesis and has implications for understanding neurodegenerative diseases.
Individuals' Medical Histories Predicted by their Noncoding Genomes
Researchers have found that analyzing mutations in regions of the genome that control genes can predict medical conditions such as hypertension, narcolepsy and heart problems.
New Source of Mutations in Cancer
Recently, a new mutation signature found in cancer cells was suspected to have been created by a family of enzymes found in human cells called the APOBEC3 family.
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!